# Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Study · id `cardio:ct-nct03829657` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03829657](<https://clinicaltrials.gov/study/NCT03829657>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03829657

Browse, organ or system: Blood vessels  
Browse, condition area: Risk and prevention  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 203 participants.

## Technical summary

Registry record NCT03829657. Randomized; triple masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2021-11-10 (actual). Results posted on 2023-01-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 203 participants (enrolled count; ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Started: 2019-02-22 (actual) (ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Primary completion: 2021-11-10 (actual) (ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Completion: 2021-11-10 (actual) (ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Results first posted: 2023-01-20 (ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Bulgaria; Canada; Denmark; Estonia; France; Germany; Hungary; Israel; Italy; New Zealand; Poland; Portugal; Russia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03829657, source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03829657-2023-01-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Acronym: REDWOOD
- Condition: Symptomatic Neurogenic Orthostatic Hypotension
- Condition: MSA
- Condition: Parkinson's Disease (PD)
- Condition: Pure Autonomic Failure (PAF)
- Intervention (Drug): ampreloxetine
- Intervention (Drug): Placebo
- Lead sponsor: Theravance Biopharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Orthostatic hypotension (`cardio:orthostatic-hypotension`)

## Provenance

Content hash: c96c917d7b632935061158ad2e4d8cf2f9da925a2042cdb9f5d259628fc358de
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
